JETIR.ORG ISSN: 2349-5162 | ESTD Year : 2014 | Monthly Issue
JOURNAL OF EMERGING TECHNOLOGIES AND INNOVATIVE RESEARCH (JETIR)
An International Scholarly Open Access, Peer-reviewed, Refereed Journal

QUALITY CONTROL AND QUALITY ASSURANCE OF TELMISARTAN TABLET: A COMPREHENSIVE REVIEW

Samarth Institute of pharmacy, Belhe

Roshani Manohar Gharat, Prachi Nandkumar Padwal, Reema Chandrakant Londhe , Pranjal Rajaram Gharat, shrutika Pralhad Gadge

1.Student, Samarth Institute of Pharmacy, Belhe, Pune.

2.Assistant professor, department of quality assurance, Samarth institute of pharmacy belhe, pune

3.Assistant Professor, Department of Quality Assurance, Samarth Institute of Pharmacy, Belhe, Pune.

4.Student, Samarth Institute of Pharmacy, Belhe, Pune.

5.Student, Samarth Institute of Pharmacy, Belhe, Pune.

Abstract

Telmisartan, an angiotensin II receptor blocker (ARB), is widely prescribed for the treatment of hypertension and related cardiovascular disorders.
Ensuring its safety, efficacy, and quality requires a robust framework of Quality Control (QC) and Quality Assurance (QA). This review highlights the regulatory requirements, analytical methodologies, critical quality attributes, and quality management systems associated with Telmisartan tablet formulations.
Additionally, it discusses current challenges and advances in pharmaceutical quality control with a focus on ensuring consistent therapeutic performance.

Keyword:-

Telmisartan**,** Hypertension**,** Diabetes, obesity, Hyperlipidemia, metabolic syndrome

1. Introduction

Hypertension is a leading global health concern, and Telmisartan is one of the most effective ARBs used in its management. As with all pharmaceutical products, maintaining quality standards is essential to ensure patient safety and therapeutic efficacy.

The pharmaceutical industry relies on two complementary systems: Quality Control (QC) and Quality Assurance (QA).Telmisartan is an oral medication that belongs to a class of drugs known as angiotensin II receptor blockers (ARBs). It is widely used to treat high blood pressure (hypertension) and to reduce the risk of serious cardiovascular events such as

heart attack and stroke. Telmisartan is available under various brand names, including Micardis, and is also available as a generic drug.

2 Regulatory Framework:-



Pharmaceutical QC and QA are guided by international and national regulatory standards:
- ICH Guidelines: Q8 (Pharmaceutical Development), Q9 (Quality Risk Management), Q10 (Pharmaceutical Quality System).
- WHO GMP Guidelines.
- US FDA & EMA Regulations.
- Indian Pharmacopoeia (IP), USP, BP, and European Pharmacopoeia (Ph. Eur.) specifications for Telmisartan.

Generic Name: Telmisartan

Brand Name: Some common brands include Micardis, Telma, and Twynsta (when combined with another drug like amlodipine).

Drug Class: Angiotensin II receptor blockers (ARBs)

Form: Typically available in tablet form.

Common Dosage: Telmisartan tablets usually come in 20 mg, 40 mg, 80 mg, and 160 mg doses.

Uses:

1.Hypertension (High Blood Pressure): Telmisartan is used to lower blood pressure, which helps reduce the risk of heart disease, stroke, and kidney problems.

2.Cardiovascular Risk Reduction: In some cases, it's used to lower the risk of heart attack, stroke, or other cardiovascular events, especially in people who have diabetes or other risk factors.

3.Heart Failure: It can be prescribed as part of the treatment for heart failure, particularly when other medications aren't well-tolerated.

Mechanism of Action:

Telmisartan selectively blocks the angiotensin II receptor (AT1 receptor), preventing the vasoconstrictive effects of angiotensin II.

This helps in reducing blood pressure, as well as preventing other complications like kidney damage in people with conditions like diabetes

Dosage:

The usual starting dose for hypertension is 40 mg once daily. The dose may be adjusted based on how well the patient responds. The maximum dose typically does not exceed 80 mg to 160 mg per day.

Side Effects:

Most people tolerate telmisartan well, but some possible side effects include:

Dizziness or lightheadedness, especially when standing up quickly.

Fatigue.

Headache.

Back pain.

Upper respiratory infections.

Elevated potassium levels (hyperkalemia) – rare but serious.

Kidney function issues – monitoring is important.

Contraindications and Cautions:

Pregnancy: Telmisartan is contraindicated during pregnancy due to the risk of harm to the fetus.

Kidney Disease: Caution is needed for people with severe kidney impairment.

High potassium levels: As it can raise potassium levels, monitoring is essential.

Liver Disease: Dose adjustments may be necessary.

Drug Interactions:

Telmisartan can interact with other blood pressure medications, such as ACE inhibitors, potassium-sparing diuretics, and certain diuretics. It may also interact with nonsteroidal anti-inflammatory drugs (NSAIDs), which can reduce its effectiveness.

3. Quality Control of Telmisartan Tablets

1.Description

Objective: To ensure uniformity in physical appearance.

Method: Visual inspection.

Specification: Tablets should be uniform in color, shape, size, and free from cracks or defects.

2.weight variations

Objective: To ensure uniform distribution of the drug among tablets.

Method: Weigh 20 tablets individually and calculate the average weight.

Specification (as per IP/USP):

±5% deviation allowed for tablets weighing >250 mg.

3. Hardness:-

Objective: To ensure mechanical strength of tablets.

Method: Use a tablet hardness tester (e.g., Monsanto or Pfizer type).

Specification: Usually 4–8 kg/cm² (depending on manufacturer).

4. Quality Assurance in Telmisartan Tablet Manufacturing

QA ensures that quality is built into every step of production through GMP, documentation, process validation, risk management, and Quality by Design (QbD).

5. Analytical Methods for Telmisartan Quality Control

HPLC is the gold standard for assay and impurity profiling.
Other methods include UV spectrophotometry, LC-MS/MS, FTIR, and XRPD for crystalline form characterization.

6. Challenges in QC/QA of Telmisartan Tablets

- Poor solubility of Telmisartan complicates dissolution testing.
- Stability issues due to moisture/light sensitivity.
- Excipient variability affecting bioavailability.
- Nitrosamine impurity monitoring requirements.

7. Future Perspectives

1.Pharmacological and Clinical Prospects

a.Expanded Therapeutic Applications

Cardiovascular protection: Telmisartan not only lowers blood pressure but also offers organ-protective effects—particularly on the heart, kidneys, and vasculature—due to its PPAR-γ modulatory activity.

2.Regulatory and Market Prospects

The global antihypertensive market is growing, driven by aging populations and increased prevalence of lifestyle diseases.

Generic Telmisartan is already widely available, but value-added generics (e.g., improved bioavailability or combination forms) will drive future market competition.

Ongoing patent expirations allow opportunities for new generic entrants and formulation innovations.

8. Conclusion

Telmisartan is an effective treatment for managing hypertension and reducing cardiovascular risk. It works by blocking angiotensin II receptors, leading to relaxation of blood vessels and lowering blood pressure. Like any medication, it's important to use it as directed by a healthcare provider, and to monitor for potential side effects, particularly if you have underlying kidney or heart conditions.

Result:-

All the tested parameters for Telmisartan 40 mg tablets met the pharmacopeial specifications. The tablets were:

Physically uniform and defect-free,

Mechanically strong with low friability,

Rapidly disintegrating and dissolving,

Chemically stable with correct potency and purity

Acknowledgments:-

I express my deep sense of gratitude to the Principal of our institution for providing the opportunity and necessary facilities to carry out this project work entitled "Quality control and quality assurance of telmisartan tablet

"I am sincerely thankful to the Head of the Department of Pharmaceutics lab for valuable guidance, constant encouragement, and academic support throughout the course of this work.

My heartfelt thanks to my project guide Ms. Prachi Padwal, who has been a source of continuous inspiration and motivation. Their expert supervision, valuable suggestions, and constructive feedback were instrumental in the successful completion of this project.

References

1.J. Tabeshpour, M. Imenshahidi, H. HosseinzadehA review of the effects of Berberis vulgaris and its major component, berberine, in metabolic syndromeIran. J. Basic Med. Sci., 20 (5) (2017), pp. 557-568

2. A. Prasad, A.A. QuyyumiRenin-angiotensin system and angiotensin receptor blockers in the metabolic syndromeCirculation, 110 (11) (2004), pp. 1507-1512

3.E.M. Rabie, G.H. Heeba, M.M. Abouzied, M.M. KhalifaComparative effects of Aliskiren and Telmisartan in high fructose diet-induced metabolic syndrome in ratsEur. J. Pharmacol., 760 (2015), pp. 145-153

4.J. Stangier, C.A. Su, W. RothPharmacokinetics of orally and intravenously administered telmisartan in healthy young and elderly volunteers and in hypertensive patientsJ. Int. Med. Res., 28 (4) (2000), pp. 149-167

5.J. Stangier, C.A. Su, P.N. van Heiningen, T. Meinicke, J.J. van Lier, H. de Bruin, et al.Inhibitory effect of telmisartan on the blood pressure response to angiotensin II challengeJ. Cardiovasc. Pharmacol., 38 (5) (2001), pp. 672-685

6.H.A. Pershadsingh, T.W. KurtzInsulin-sensitizing effects of telmisartan: implications for treating insulin-resistant hypertension and cardiovascular diseaseDiabetes Care, 27 (4) (2004), p. 1015

7.CrossrefView in ScopusGoogle Scholar[24]M. Rakhshandehroo, B. Knoch, M. Müller, S. KerstenPeroxisome proliferator-activated receptor alpha target genesPPAR Res., 2010 (2010)

8.W.T. Wong, X.Y. Tian, A. Xu, J. Yu, C.W. Lau, R.L. Hoo, et al.Adiponectin is required for PPARγ-mediated improvement of endothelial function in diabetic miceCell Metab., 14 (1) (2011), pp. 104-115

9.P. Balakumar, S. KathuriaSubmaximal PPARγ activation and endothelial dysfunction: new perspectives for the management of cardiovascular disordersBr. J. Pharmacol., 166 (7) (2012), pp. 1981-1992

10.G. Wang, J. Wei, Y. Guan, N. Jin, J. Mao, X. WangPeroxisome proliferator-activated receptor-gamma agonist rosiglitazone reduces clinical inflammatory responses in type 2 diabetes with coronary artery disease after coronary angioplastyMetabolism, 54 (5) (2005), pp. 590-597

11. M.V. Liberato, A.S. Nascimento, S.D. Ayers, J.Z. Lin, A. Cvoro, R.L. Silveira, et al.Medium chain fatty acids are selective peroxisome proliferator activated receptor (PPAR) γ activators and pan-PPAR partial agonistsPLoS One, 7 (5) (2012), Article e36297

12. P. Chinnam, M. Mohsin, L.M. ShafeeEvaluation of acute toxicity of pioglitazone in miceToxicol. Int., 19 (3) (2012), pp. 250-254

13.MD) B. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet].): Telmisartan. [.].: National Institute of Diabetes and Digestive and Kidney Diseases; 2017.

14.K. Henriksen, I. Byrjalsen, P. Qvist, H. Beck-Nielsen, G. Hansen, B.J. Riis, et al.Efficacy and safety of the PPARγ partial agonist balaglitazone compared with pioglitazone and placebo: a phase III, randomized, parallel-group study in patients with type 2 diabetes on stable insulin therapy

15.J. Zhang, X. Liu, X.B. Xie, X.C. Cheng, R.L. WangMultitargeted bioactive ligands for PPARs discovered in the last decadeChem. Biol. Drug Des., 88 (5) (2016), pp. 635-663

16.T. Haraguchi, K. Iwasaki, K. Takasaki, K. Uchida, T. Naito, A. Nogami, et al.Telmisartan, a partial agonist of peroxisome proliferator-activated receptor gamma, improves impairment of spatial memory and hippocampal apoptosis in rats treated with repeated cerebral ischemiaBrain Res., 1353 (2010), pp. 125-132

17.Y. Amano, T. Yamaguchi, K. Ohno, T. Niimi, M. Orita, H. Sakashita, et al.Structural basis for telmisartan-mediated partial activation of PPAR gamma

18.T.G. Marshall, R.E. Lee, F.E. MarshallCommon angiotensin receptor blockers may directly modulate the immune system via VDR, PPAR and CCR2bTheor. Biol. Med. Model., 3 (1) (2006)

19.R. Clasen, M. Schupp, A. Foryst-Ludwig, C. Sprang, M. Clemenz, M. Krikov, et al.PPARgamma-activating angiotensin type-1 receptor blockers induce adiponectinHypertension, 46 (1) (2005), pp. 137-143

20. K. Ushijima, M. Takuma, H. Ando, E. Ishikawa-Kobayashi, M. Nozawa, T. Maekawa, et al.Effects of telmisartan and valsartan on insulin sensitivity in obese diabetic miceEur. J. Pharmacol., 698 (1-3) (2013), pp. 505-510

21.S. Yusuf, H.C. Diener, R.L. Sacco, D. Cotton, S. Ounpuu, W.A. Lawton, et al.Telmisartan to prevent recurrent stroke and cardiovascular eventsNew Engl. J. Med., 359 (12) (2008), pp. 1225-1237

22.H. Nakagami, R. MorishitaObesity and gastrointestinal hormones-dual effect of angiotensin II receptor blockade and a partial agonist of PPAR-γCurr. Vasc. Pharmacol., 9 (2) (2011), pp. 162-166

23.E. Rawish, L. Nickel, F. Schuster, I. Stölting, A. Frydrychowicz, K. Saar, et al.Telmisartan prevents development of obesity and normalizes hypothalamic lipid dropletsJ. Endocrinol., 244 (1) (2020), pp. 95-110

24.G.J. Choi, H.M. Kim, H. Kang, J. KimEffects of telmisartan on fat distribution: a meta-analysis of randomized controlled trialsCurr. Med. Res. Opin., 32 (7) (2016), pp. 1303-1309

25.K. Noma, K. Toshinai, K. Koshinaka, M. NakazatoTelmisartan suppresses food intake in mice via the manicotti pathwayObes. Res. Clin. Pract., 5 (2) (2011), pp. e79-e156